Last reviewed · How we verify
Relugolix-Containing Product — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Relugolix-Containing Product (Relugolix-Containing Product) — Sumitomo Pharma Switzerland GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Relugolix-Containing Product TARGET | Relugolix-Containing Product | Sumitomo Pharma Switzerland GmbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Relugolix-Containing Product CI watch — RSS
- Relugolix-Containing Product CI watch — Atom
- Relugolix-Containing Product CI watch — JSON
- Relugolix-Containing Product alone — RSS
Cite this brief
Drug Landscape (2026). Relugolix-Containing Product — Competitive Intelligence Brief. https://druglandscape.com/ci/relugolix-containing-product. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing